Actively Enrolling Two Phase III Clinical
Studies in NSCLC for Ivonescimab: HARMONi and HARMONi-3
Updated Phase II Data Announced for Ivonescimab
Highlighting 24-Month OS Rate of 64.8% in 1L Squamous NSCLC
Patients and mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC
Patients
SITC 2023 Poster Presentation Featured Novel
Cooperative Binding Characteristics of Ivonescimab, Enabling Higher
Affinity and Avidity in the Tumor Microenvironment
Updated Guidance to Extend Cash Runway for
Operations into Q1 2025, versus Prior Guidance of Q3 2024
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the
"Company") today reports its financial results and provides an
update on its operational progress for the fourth quarter and
year-ended December 31, 2023.
Operational & Corporate Updates
- Our operational progress continues with ivonescimab (SMT112),
an investigational, potentially first-in-class bispecific antibody
combining the effects of immunotherapy via a blockade of PD-1 with
the anti-angiogenesis effects associated with blocking VEGF into a
single molecule:
- We are actively engaged in development activities for
ivonescimab. In just over one year since we closed our in-licensing
transaction for ivonescimab, we have:
- Held multiple meetings with the US Food & Drug
Administration (FDA) regarding our planned Phase III clinical
program and incorporated this feedback accordingly.
- Begun our clinical development in non-small cell lung cancer
(NSCLC) and are actively enrolling two Phase III trials in the
following proposed indications:
- HARMONi Phase III Trial: Ivonescimab combined with chemotherapy
in patients with epidermal growth factor receptor (EGFR)-mutated,
locally advanced or metastatic non-squamous NSCLC who have
progressed after treatment with a third-generation EGFR tyrosine
kinase inhibitor (TKI), with enrollment completion expected in the
second half of 2024, and
- HARMONi-3 Phase III Trial: Ivonescimab combined with
chemotherapy in first-line metastatic squamous NSCLC patients, with
the first patient having been treated in the fourth quarter of
2023.
- In November 2023, a poster presentation was featured at the
38th Annual Meeting of the Society for Immunotherapy of Cancer
(SITC) highlighting the novel mechanism of action and enhanced
binding characteristics of ivonescimab. The tetravalent structure
(four binding sites) of ivonescimab enables higher avidity
(accumulated strength of multiple binding interactions) in the
tumor microenvironment with over 18-fold increased binding affinity
to PD-1 in the presence of VEGF in vitro, and over 4-times
increased binding affinity to VEGF in the presence of PD-1 in
vitro.1
- In addition to promising Phase II data presented at the 2023
American Society of Clinical Oncology (ASCO) Annual Meeting, Akeso
announced updates to the Phase II data in January 2024. Notably, in
patients with first line advanced or metastatic NSCLC without
actionable genomic alterations (Cohort 1, n=63), a 24-month overall
survival (OS) rate of 64.8% was observed. Additionally, in patients
with advanced or metastatic NSCLC whose tumors are positive for
EGFR mutations and have progressed following an EGFR TKI (Cohort 2,
n=19), median OS of 22.5 months was achieved. Treatment-related
adverse events leading to discontinuation of ivonescimab was 11%
and 0% in the two populations, respectively; there were no
treatment related adverse events leading to a patient's death in
either setting.2 AK112-201 is a study of Chinese subjects conducted
and analyzed by our partners, Akeso, of which the updated data
supports Summit's HARMONi and HARMONi-3 Phase III clinical
trials.
- Recapping our Collaboration and License Agreement with Akeso
Inc. (Akeso) for ivonescimab (SMT112):
- On December 5, 2022, Summit and Akeso entered into a
Collaboration and License Agreement for ivonescimab, which closed
on January 17, 2023.
- Summit received the rights to develop and commercialize
ivonescimab in the United States, Canada, Europe, and Japan. Akeso
retains the development and commercialization rights for the rest
of the world, including China.
- In exchange for these rights, Summit made an upfront payment of
$500 million in 2023.
- Akeso will be eligible to receive regulatory and commercial
milestones of up to $4.5 billion. In addition, Akeso will receive
low double-digit royalties on net sales in the Summit
territories.
- Over 1,600 patients have been treated with ivonescimab in
clinical studies globally.
- Akeso has a rich and diversified antibody drug pipeline with
over 30 internally discovered drug candidates in various stages of
development, including at least six bispecific antibodies. Akeso
has taken part in over 120 clinical trials for 19 drug candidates.
Akeso has two drugs approved for oncology indications in China: a
PD-1 inhibitor and a novel PD-1 / CTLA-4 bispecific antibody. Akeso
has over 2,800 employees.
Financial Highlights
Cash and Cash Equivalents, Restricted
Cash, & Short-term Investments
- Aggregate cash and cash equivalents, restricted cash, and
short-term investments were $186.2 million and $648.6 million at
December 31, 2023 and 2022, respectively. Accounts receivable and
research and development tax credits were $1.8 million and $6.1
million at December 31, 2023 and 2022, respectively.
- Our short-term investments consist of U.S. treasury
securities.
- Our current notes payable balance as of December 31, 2023 was
$100.0 million, and matures April 1, 2025. On February 17, 2024,
this $100.0 million note from Robert W. Duggan, Chairman & CEO,
was amended, extending the maturity date from September 6, 2024 to
April 1, 2025, and making interest payments due at maturity. For
all applicable periods commencing February 17, 2024, interest shall
accrue on the outstanding principal balance at the greater of 12%
or the U.S. prime interest rate, as reported in the Wall Street
Journal, plus 350 basis points, adjusted monthly, compounded
quarterly.
- Operating cash outflow for 2023 and 2022 was $76.8 million and
$41.6 million, respectively.
Updated Cash Guidance
- With the extension of the $100.0 million note, we updated our
cash guidance such that we now have sufficient cash to operate into
the first quarter of 2025. Our prior cash guidance was to have
sufficient funds going into September 2024.
GAAP and Non-GAAP Research and Development
(R&D) Expenses
- R&D expenses according to generally accepted accounting
principles in the U.S. (“GAAP”) were $24.8 million for the fourth
quarter of 2023, as compared to $5.4 million for the same period of
the year prior. The increase is due to increases in clinical study
and development costs related to ivonescimab and increases in
people cost, including stock-based compensation, as we continue to
build out R&D team.
- Non-GAAP R&D expenses were $22.4 million for the fourth
quarter of 2023, as compared to $4.4 million for the same period of
the year period.
GAAP and Non-GAAP General and
Administrative (G&A) Expenses
- GAAP G&A expenses were $11.6 million for the fourth quarter
of 2023, as compared to $7.6 million for the same period of the
year prior. The increase is due to increase in stock-based
compensation as we continue to build our team.
- Non-GAAP G&A expenses were $5.3 million for the fourth
quarter of 2023, as compared to $5.9 million for the same period of
the year prior.
GAAP and Non-GAAP Net Loss
- GAAP net loss in the fourth quarter of 2023 and 2022 was $36.6
million or $0.05 per basic and diluted share, and $19.3 million or
$0.07 per basic and diluted share, respectively. Non-GAAP net loss
in the fourth quarter of 2023 and 2022 was $27.9 million or $0.04
per basic and diluted share, and $8.1 million or $0.03 per basic
and diluted share, respectively.
- GAAP net loss in 2023 and 2022 was $614.9 million or $0.99 per
basic and diluted share, and $78.8 million or $0.41 per basic and
diluted share, respectively. The increase from prior year was
primarily related to IPR&D expenses associated with the
in-licensing of ivonescimab from Akeso and investments in the
development of ivonescimab. Non-GAAP net loss in 2023 and 2022 was
$79.9 million or $0.13 per basic and diluted share, and $58.4
million or $0.30 per basic and diluted share, respectively.
Use of Non-GAAP Financial
Results
This release includes measures that are not in accordance with
U.S. generally accepted accounting principles (“Non-GAAP
measures”). These Non-GAAP measures should be viewed in addition
to, and not as a substitute for, Summit's reported GAAP results,
and may be different from Non-GAAP measures used by other
companies. In addition, these Non-GAAP measures are not based on
any comprehensive set of accounting rules or principles. Summit
management uses these Non-GAAP measures for internal budgeting and
forecasting purposes and to evaluate Summit’s financial
performance. Summit management believes the presentation of these
Non-GAAP measures is useful to investors for comparing prior
periods and analyzing ongoing business trends and operating
results. For further information regarding these Non-GAAP measures,
please refer to the tables presenting reconciliations of our
Non-GAAP results to our U.S. GAAP results and the “Notes on our
Non-GAAP Financial Information” at the end of this press
release.
Fourth Quarter and Year-end 2023 Earnings Call
Summit will host an earnings call this morning, Tuesday,
February 20, 2024, at 9:00am ET. The conference call will be
accessible by dialing (888) 210-3702 (toll-free domestic) or (646)
960-0191 (international) using conference code 5785899. A live
webcast and instructions for joining the call are accessible
through Summit’s website www.smmttx.com. An archived edition of the
webcast will be available on our website after the call.
About Ivonescimab
Ivonescimab, known as SMT112 in Summit’s license territories,
the United States, Canada, Europe, and Japan, and as AK112 in China
and Australia, is a novel, potential first-in-class investigational
bispecific antibody combining the effects of immunotherapy via a
blockade of PD-1 with the anti-angiogenesis effects associated with
blocking VEGF into a single molecule. Ivonescimab displays unique
cooperative binding to each of its intended targets with higher
affinity when in the presence of both PD-1 and VEGF.
This could differentiate ivonescimab as there is potentially
higher expression (presence) of both PD-1 and VEGF in tumor tissue
and the tumor microenvironment (TME) as compared to normal tissue
in the body. Ivonescimab’s tetravalent structure (four binding
sites) enables higher avidity (accumulated strength of multiple
binding interactions) in the tumor microenvironment with over
18-fold increased binding affinity to PD-1 in the presence of VEGF
in vitro, and over 4-times increased binding affinity to VEGF in
the presence of PD-1 in vitro.3 This tetravalent structure, the
intentional novel design of the molecule, and bringing these two
targets into a single bispecific antibody with cooperative binding
qualities have the potential to direct ivonescimab to the tumor
tissue versus healthy tissue. The intent of this design is to
improve upon previously established efficacy thresholds, in
addition to side effects and safety profiles associated with these
targets.
Ivonescimab was discovered by Akeso Inc. (HKEX Code: 9926.HK)
and is currently engaged in multiple Phase III clinical trials.
Summit has begun its clinical development of ivonescimab in NSCLC,
commencing enrollment in 2023 in its two Phase III clinical trials.
Over 1,600 patients have been treated with ivonescimab in clinical
studies globally.
Ivonescimab is an investigational therapy that is not approved
by any regulatory authority.
About Lung Cancer
Lung cancer is believed to impact approximately 600,000 people
across the United States, United Kingdom, Spain, France, Italy,
Germany, and Japan.4 NSCLC is the most prevalent type of lung
cancer and represents approximately 80% to 85% of all incidences.5
Among patients with non-squamous NSCLC, approximately 15% have
EGFR-sensitizing mutations in the United States and Europe.6
Patients with squamous histology represent approximately 25% to 30%
of NSCLC patients.7
About Summit Therapeutics
Summit was founded in 2003 and our shares are listed on the
Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in
Miami, Florida, and we have additional offices in Menlo Park,
California and Oxford, United Kingdom.
Summit’s mission, in part, is to develop patient, physician,
caregiver, and societal-friendly medicinal therapies intended to
improve quality of life, increase potential duration of life, and
resolve serious unmet medical needs.
For more information, please visit https://www.smmttx.com and
follow us on X (formerly Twitter) @summitplc.
Summit Forward-looking Statements
Any statements in this press release about the Company’s future
expectations, plans and prospects, including but not limited to,
statements about the clinical and preclinical development of the
Company’s product candidates, entry into and actions related to the
Company’s partnership with Akeso Inc., the Company's anticipated
spending and cash runway, the therapeutic potential of the
Company’s product candidates, the potential commercialization of
the Company’s product candidates, the timing of initiation,
completion and availability of data from clinical trials, the
potential submission of applications for marketing approvals,
potential acquisitions, and other statements containing the words
"anticipate," "believe," "continue," "could," "estimate," "expect,"
"intend," "may," "plan," "potential," "predict," "project,"
"should," "target," "would," and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements
as a result of various important factors, including the results of
our evaluation of the underlying data in connection with the
development and commercialization activities for ivonescimab, the
outcome of discussions with regulatory authorities, including the
Food and Drug Administration, the uncertainties inherent in the
initiation of future clinical trials, availability and timing of
data from ongoing and future clinical trials, the results of such
trials, and their success, and global public health crises, that
may affect timing and status of our clinical trials and operations,
whether preliminary results from a clinical trial will be
predictive of the final results of that trial or whether results of
early clinical trials or preclinical studies will be indicative of
the results of later clinical trials, whether business development
opportunities to expand the Company’s pipeline of drug candidates,
including without limitation, through potential acquisitions of,
and/or collaborations with, other entities occur, expectations for
regulatory approvals, laws and regulations affecting government
contracts and funding awards, availability of funding sufficient
for the Company’s foreseeable and unforeseeable operating expenses
and capital expenditure requirements and other factors discussed in
the "Risk Factors" section of filings that the Company makes with
the Securities and Exchange Commission. Any change to our ongoing
trials could cause delays, affect our future expenses, and add
uncertainty to our commercialization efforts, as well as to affect
the likelihood of the successful completion of clinical development
of ivonescimab. Accordingly, readers should not place undue
reliance on forward-looking statements or information. In addition,
any forward-looking statements included in this press release
represent the Company’s views only as of the date of this release
and should not be relied upon as representing the Company’s views
as of any subsequent date. The Company specifically disclaims any
obligation to update any forward-looking statements included in
this press release.
Summit Therapeutics
Inc.
GAAP Condensed Consolidated
Statements of Operations
In millions, except per share
data
Three Months Ended
December 31,
Twelve Months Ended
December 31,
2023
2022
2023
2022
Revenue
$
—
$
—
$
—
$
0.7
Operating expenses:
Research and development
24.8
5.4
59.4
52.0
General and administrative
11.6
7.6
30.3
26.7
In-process research and development
—
—
520.9
—
Impairment of intangible assets
8.5
—
8.5
Total operating expenses
36.4
21.5
610.6
87.2
Other operating income, net
0.2
1.1
1.0
14.4
Operating loss
(36.2
)
(20.4
)
(609.6
)
(72.1
)
Other (expense) income, net
(0.4
)
1.1
(5.3
)
(6.7
)
Net loss
$
(36.6
)
$
(19.3
)
$
(614.9
)
$
(78.8
)
Basic and diluted loss per share
$
(0.05
)
$
(0.07
)
$
(0.99
)
$
(0.41
)
Summit Therapeutics
Inc.
GAAP Condensed Consolidated
Balance Sheet Information
In millions
December 31,
2023
December 31,
2022
Cash and cash equivalents, restricted
cash, and short-term investments
$
186.2
$
648.6
Total assets
$
202.9
$
664.2
Total liabilities
$
125.3
$
537.5
Total stockholders' equity
$
77.7
$
126.7
Summit Therapeutics
Inc.
GAAP Condensed Consolidated
Statement of Cash Flows Information
In millions
Twelve Months Ended December
31,
2023
2022
Net cash used in operating
activities
$
(76.8
)
$
(41.6
)
Net cash used in investing
activities
(587.8
)
(0.6
)
Net cash provided by financing
activities
86.5
620.2
Effect of exchange rate changes on
cash
0.8
(1.2
)
(Decrease) increase in cash and cash
equivalents
$
(577.3
)
$
576.8
Summit Therapeutics
Inc.
Schedule Reconciling Selected
Non-GAAP Financial Measures
(in millions, except share and
per share data)
Three Months Ended
December 31,
Twelve Months Ended
December 31,
2023
2022
2023
2022
Reconciliation of GAAP to Non-GAAP
Research and Development Expense
GAAP Research and Development
$
24.8
$
5.4
$
59.4
$
52.0
Stock-based compensation (Note 1)
(2.4
)
(1.0
)
(4.4
)
(4.3
)
Non-GAAP Research and Development
$
22.4
$
4.4
55.0
$
47.7
Reconciliation of GAAP to Non-GAAP
General and Administrative Expenses
GAAP General and administrative
$
11.6
$
7.6
$
30.3
$
26.7
Stock-based compensation (Note 1)
(6.3
)
(1.7
)
(9.7
)
(7.6
)
Non-GAAP General and administrative
$
5.3
$
5.9
20.6
$
19.1
Reconciliation of GAAP to Non-GAAP
In-Process Research and Development Expenses
GAAP In-process research and
development
$
—
$
—
$
520.9
$
—
In-process research and development (Note
2)
—
—
(520.9
)
—
Non-GAAP In-process research and
development
$
—
$
—
—
$
—
Reconciliation of GAAP to Non-GAAP
Impairment of Intangible Assets
GAAP Impairment of intangible assets
$
—
$
8.5
$
—
$
8.5
Impairment of intangible assets (Note
3)
—
(8.5
)
—
(8.5
)
Non-GAAP Impairment of intangible
assets
$
—
$
—
$
—
$
—
Reconciliation of GAAP to Non-GAAP
Operating Expenses
GAAP Operating expenses
$
36.4
$
21.4
$
610.6
$
87.2
Stock-based compensation (Note 1)
(8.7
)
(2.7
)
(14.1
)
(11.9
)
In-process research and development (Note
2)
—
—
(520.9
)
—
Impairment of intangible assets (Note
3)
—
(8.5
)
—
(8.5
)
Non-GAAP Operating expense
$
27.7
$
10.3
$
75.6
$
66.8
Reconciliation of GAAP Net Loss to
Non-GAAP Net Loss
GAAP Net Loss
$
(36.6
)
$
(19.3
)
$
(614.9
)
$
(78.8
)
Stock-based compensation (Note 1)
8.7
2.7
14.1
11.9
In-process research and development (Note
2)
—
—
520.9
—
Impairment of intangible assets (Note
3)
—
8.5
—
8.5
Non-GAAP Net Loss
$
(27.9
)
$
(8.1
)
$
(79.9
)
$
(58.4
)
Reconciliation of GAAP EPS to Non-GAAP
EPS
GAAP Loss Per Share
$
(0.05
)
$
(0.07
)
$
(0.99
)
$
(0.41
)
Stock-based compensation (Note 1)
0.01
0.01
0.02
0.06
In-process research and development (Note
2)
—
—
0.84
—
Impairment of intangible assets (Note
3)
—
0.03
—
0.04
Non-GAAP Loss Per Share
$
(0.04
)
$
(0.03
)
$
(0.13
)
$
(0.30
)
Basic and Diluted Weighted Average Shares
Outstanding
700.6
286.8
619.6
193.3
Summit Therapeutics, Inc. Notes on
our Non-GAAP Financial Information
Non-GAAP financial measures adjust GAAP financial measures for
the items listed below. These Non-GAAP measures should be viewed in
addition to, and not as a substitute for Summit's reported GAAP
results, and may be different from Non-GAAP measures used by other
companies. In addition, these Non-GAAP measures are not based on
any comprehensive set of accounting rules or principles. Summit
management uses these Non-GAAP measures for internal budgeting and
forecasting purposes and to evaluate Summit’s financial
performance. Summit management believes the presentation of these
Non-GAAP measures is useful to investors for comparing prior
periods and analyzing ongoing business trends and operating
results.
Each of non-GAAP Research and Development Expense, non-GAAP
General and Administrative Expenses, non-GAAP Operating Expenses,
non-GAAP Net Loss and Non-GAAP EPS differ from GAAP in that such
measures exclude the non-cash charges and costs associated with
stock-based compensation. In addition, (i) non-GAAP Operating
Expenses, non-GAAP Net Loss and non-GAAP EPS each exclude certain
one-time charges associated with in-process research and
development and impairment of intangible assets, (ii) non-GAAP
In-Process Research and Development Expenses excludes certain
in-process research and development charges and (iii) non-GAAP
Impairment of Intangible Assets excludes certain one-time
impairment charges, in each case as described further in the notes
below and as expressed in the tabular reconciliation presented
above.
Note 1: Stock-based compensation is a non-cash charge and costs
calculated for this expense can vary year-over-year depending on
the stock price of awards on the date of grant as well as the
timing of compensation award arrangements.
Note 2: In-process research and development represents a
one-time charge associated with the Company's in-licensing of
ivonescimab from Akeso.
Note 3: The Company determined that it would cease investment in
the Discuva Platform in 2022 and focus on the therapeutic area of
oncology and as such recognized an impairment charge for the
carrying value.
Appendix: Glossary of Critical Terms Contained Herein
Affinity – Affinity is the strength of binding of a
molecule, such as a protein or antibody, to another molecule, such
as a ligand.
Avidity – Avidity is the accumulated strength of multiple
binding interactions.
Angiogenesis – Angiogenesis is the development,
formation, and maintenance of blood vessel structures. Without
sufficient blood flow, tissue may experience hypoxia (insufficient
oxygen) or lack of nutrition, which may cause cell death.8
Cooperative binding – Cooperative binding occurs when the
number of binding sites on the molecule that can be occupied by a
specific ligand (e.g., protein) is impacted by the ligand’s
concentration. For example, this can be due to an affinity for the
ligand that depends on the amount of ligand bound or the binding
strength of the molecule to one ligand based on the concentration
of another ligand, increasing the chance of another ligand binding
to the compound.9
Immunotherapy – Immunotherapy is a type of treatment,
including cancer treatments, that help a person’s immune system
fight cancer. Examples include anti-PD-1 therapies.10
PD-1 – Programmed cell Death protein 1 is a protein on
the surface of T cells and other cells. PD-1 plays a key role in
reducing the regulation of ineffective or harmful immune responses
and maintaining immune tolerance. However, with respect to cancer
tumor cells, PD-1 can act as a stopping mechanism (a brake or
checkpoint) by binding to PD-L1 ligands that exist on tumor cells
and preventing the T cells from targeting cancerous tumor
cells.11
PD-L1 – Programmed cell Death Ligand 1 is expressed by
cancerous tumor cells as an adaptive immune mechanism to escape
anti-tumor responses, thus believed to suppress the immune system’s
response to the presence of cancer cells.12
PD-L1 TPS – PD-L1 Tumor Proportion Score represents the
percentage of tumor cells that express PD-L1 proteins.
PFS – Progression-Free Survival.
SQ-NSCLC – Non-small cell lung cancer tumors of squamous
histology.
T Cells – T cells are a type of white blood cell that is
a component of the immune system that, in general, fights against
infection and harmful cells like tumor cells.13
Tetravalent – A tetravalent molecule has four binding
sites or regions.
Tumor Microenvironment – The tumor microenvironment is
the ecosystem that surrounds a tumor inside the body. It includes
immune cells, the extracellular matrix, blood vessels and other
cells, like fibroblasts. A tumor and its microenvironment
constantly interact and influence each other, either positively or
negatively.14
VEGF – Vascular Endothelial Growth Factor is a signaling
protein that promotes angiogenesis.15
_________________________
1 Zhong, et al, SITC 2023 2 Akeso, Inc. Press Release, January
8, 2024 3 Zhong, et al, SITC 2023 4 American Cancer Society:
www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html
(Accessed Jan 2024); World Health Organization: International
Agency for Research on Cancer, Globocan data by country (UK, Spain,
France, Italy, Germany); Japan National Cancer Registry. 5 Schabath
MB, Cote ML. Cancer Progress and Priorities: Lung Cancer. Cancer
Epidemiology, Biomarkers & Prevention. (2019). 6 About
EGFR-Positive Lung Cancer | Navigating EGFR (lungevity.org) 7
Schabath MB, Cote ML. Cancer Progress and Priorities: Lung Cancer.
Cancer Epidemiology, Biomarkers & Prevention. (2019). 8 Shibuya
M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor
(VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and
Pro-Angiogenic Therapies. Genes Cancer. 2011 Dec;2(12):1097-105. 9
Stefan MI, Le Novère N. Cooperative binding. PLoS Comput Biol.
2013;9(6) 10 US National Cancer Institute, a part of the National
Institute of Health (NIH).
https://www.cancer.gov/about-cancer/treatment/types/immunotherapy.
Accessed October 2023. 11 Han Y, et al. PD-1/PD-L1 Pathway: Current
Researches in Cancer. Am J Cancer Res. 2020 Mar 1;10(3):727-742. 12
Han Y, et al. PD-1/PD-L1 Pathway: Current Researches in Cancer. Am
J Cancer Res. 2020 Mar 1;10(3):727-742. 13 Cleveland Clinic.
https://my.clevelandclinic.org/health/body/24630-t-cells. Accessed
October 2023. 14 MD Anderson Cancer Center.
https://www.mdanderson.org/cancerwise/what-is-the-tumor-microenvironment-3-things-to-know.h00-159460056.html.
Accessed October 2023. 15 Shibuya M. Vascular Endothelial Growth
Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A
Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes
Cancer. 2011 Dec;2(12):1097-105.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240220111373/en/
Contact Summit Investor Relations: Dave Gancarz Chief
Business & Strategy Officer
Nathan LiaBraaten Senior Director, Investor Relations
investors@smmttx.com
Summit Therapeutics (NASDAQ:SMMT)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Summit Therapeutics (NASDAQ:SMMT)
Gráfica de Acción Histórica
De May 2023 a May 2024